Abstract:Background: 5-Hydroxymethylcytosine (5-hmC), a stable epigenetic marker, is closely related to tumor staging, recurrence and survival, but the prognostic value of 5-hmC in primary testicular diffuse large B-cell lymphoma (PT-DLBCL) remains unclear. This study aimed to investigate the 5-hmC expression in PT-DLBCL and evaluate its prognostic value. Methods: A total of 34 patients with PT-DLBCL treated in the Department of Hematology from August 2000 to August 2020 were included in this study. The expression of 5-hmC in PT-DLBCL tissues and normal testicular tissues were assessed by immunohistochemistry. 5-hmC staining is estimated as a percentage under every nuclear staining intensity score (0-3), 0 or 1 of which were regarded as 5-hmC reduction. The quantification of 5-hmC reduction is defined as the percentage of cells with 5-hmC staining scores of 0 and 1. According 5-hmC reduction of 80%, a 5-hmC reduction of <80% is regarded as "5-hmC high-level group", and a 5-hmC reduction of ≥80% is regarded as "5-hmC low-level group". Furthermore, Cox regression model was used to evaluate the prognostic value of all covariates. Results: The median percentage of 5-hmC reduction in the PT-DLBCL group was 77.50% (60%-90%), the median 5-hmC reduction in the normal testicular tissues was 30% (20%-50%). Compared with normal testicular tissue, 5-hmC levels in PT-DLBCL tissue were significantly decreased (p<0.05). Of the 34 PT-DLBCL patients, 17 had tumors with relatively low 5-hmC expression (5-hmC reduction of ≥80%) and 17 had tumors with relatively high 5-hmC expression (5-hmC reduction of < 80%). 5-hmC expression was negatively correlated with international prognostic index (p = 0.037), while there was no significant difference in 5-hmC decrease among different groups of age at diagnosis, lactate dehydrogenase, testicular lymphoma involvement (unilateral or bilateral), Ki-67 and tumor diameter. Relatively low 5-hmC expression indicated shorter overall survival (OS) (5-year OS 50.2% vs 81.3%, p=0.022) and progression-free survival (PFS) (5-year PFS 38.5% vs 70.7%, p=0.001). Cox multivariate analysis of IPI (2-3 vs. 0-1), intrathecal prophylaxis (No vs. Yes), and 5-hmC reduction (≥80% vs. <80%) showed that 5-hmC reduction ≥80% (hazard ratio: 7.252, p = 0.005) and not receiving intrathecal prophylaxis (hazard ratio: 7.207, p =0.001) are independent risk factors for poor prognosis of PT-DLBCL. Conclusion: Our results suggested that 5-hmC decline can be identified as a poor prognostic predictor for PT-DLBCL. It is necessary to further explore the underlying mechanism of this epigenetic marker to identify methods to re-establish 5-hmC levels and provide new targets for cancer therapy.

Prognostic Value of Downregulated 5-Hydroxymethylcytosine Expression in Renal Cell Carcinoma: a 10 Year Follow-Up Retrospective Study.

A Novel DNA Methylation Signature Revealed GDF6 and RCC1 As Potential Prognostic Biomarkers Correlated with Cell Proliferation in Clear Cell Renal Cell Carcinoma

A five-gene methylation signature predicts overall survival of patients with clear cell renal cell carcinoma

The Level and Clinical Significance of 5-Hydroxymethylcytosine in Oral Squamous Cell Carcinoma: an Immunohistochemical Study in 95 Patients.

Low Level of 5-Hydroxymethylcytosine Predicts Poor Prognosis in Non-Small Cell Lung Cancer

Development and Validation of an Integrative Methylation Signature and Nomogram for Predicting Survival in Clear Cell Renal Cell Carcinoma

Identification of Differentially Methylated Genes Associated with Clear Cell Renal Cell Carcinoma and Their Prognostic Values

Decreased 5-Hydroxymethylcytosine (5-Hmc) Predicts Poor Prognosis in Early-Stage Laryngeal Squamous Cell Carcinoma.

MCM5 promotes tumour proliferation and correlates with the progression and prognosis of renal cell carcinoma

A CpG-methylation-based Assay to Predict Survival in Clear Cell Renal Cell Carcinoma

Integrative 5-Methylcytosine Modification Immunologically Reprograms Tumor Microenvironment Characterizations and Phenotypes of Clear Cell Renal Cell Carcinoma

A prognostic signature based on genes associated with m6A/m5C/m1A/m7G modifications and its immunological characteristics in clear cell renal cell carcinoma

Diagnostic and prognostic value of m5C regulatory genes in hepatocellular carcinoma

Decreased 5-Hydroxymethylcytosine (5-Hmc) is an Independent Poor Prognostic Factor in Gastric Cancer Patients

Global Changes of 5-Hydroxymethylcytosine and 5-Methylcytosine from Normal to Tumor Tissues Are Associated with Carcinogenesis and Prognosis in Colorectal Cancer

The epigenetic modifier CHD5 functions as a novel tumor suppressor for renal cell carcinoma and is predominantly inactivated by promoter CpG methylation.

Loss of 5-Hydroxymethylcytosine is an Independent Unfavorable Prognostic Factor for Esophageal Squamous Cell Carcinoma

Identification of a Methylation-Regulating Genes Prognostic Signature to Predict the Prognosis and Aid Immunotherapy of Clear Cell Renal Cell Carcinoma

Cell-Free DNA 5-Hydroxymethylcytosine Signatures for Lung Cancer Prognosis

Identification of a novel 5-methylcytosine-related signature for prognostic prediction of kidney renal papillary cell carcinoma and a Putative target for drug repurposing

Loss of 5-Hydroxymethylcytosine As a Poor Prognostic Factor for Primary Testicular Diffuse Large B-cell Lymphoma.